Literature DB >> 12022938

A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models.

R G Richards1, F C Sampson, S M Beard, P Tappenden.   

Abstract

Entities:  

Mesh：

Year:  2002        PMID： 12022938     DOI： 10.3310/hta6100

Source DB:  PubMed          Journal:  Health Technol Assess        ISSN： 1366-5278            Impact factor:   4.014


× No keyword cloud information.
  37 in total

1.  Sativex(®) and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis.

Authors:  Letizia Leocani; Arturo Nuara; Elise Houdayer; Irene Schiavetti; Ubaldo Del Carro; Stefano Amadio; Laura Straffi; Paolo Rossi; Vittorio Martinelli; Carlos Vila; Maria Pia Sormani; Giancarlo Comi
Journal:  J Neurol       Date:  2015-08-20       Impact factor: 4.849

Review 2.  Measures of physical and cognitive function and work status among individuals with multiple sclerosis: a review of the literature.

Authors:  Lisa A Pompeii; Samuel D Moon; Douglas C McCrory
Journal:  J Occup Rehabil       Date:  2005-03

3.  Clinically isolated syndrome and multiple sclerosis: rethinking the arsenal.

Authors:  Krupa Pandey; Fred D Lublin
Journal:  Curr Treat Options Neurol       Date:  2009-05       Impact factor: 3.598

4.  Multiple sclerosis in the UK: service use, costs, quality of life and disability.

Authors:  Paul McCrone; Margaret Heslin; Martin Knapp; Paul Bull; Alan Thompson
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

5.  Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis.

Authors:  Michael G Serpell; William Notcutt; Christine Collin
Journal:  J Neurol       Date:  2012-08-10       Impact factor: 4.849

6.  An assessment of the feasibility and utility of the MS symptom and impact diary (MSSID).

Authors:  Joanne Greenhalgh
Journal:  Qual Life Res       Date:  2005-06       Impact factor: 4.147

Review 7.  Does pain in individuals with multiple sclerosis affect employment? A systematic review and meta-analysis.

Authors:  Shahnaz Shahrbanian; Mohammad Auais; Pierre Duquette; Katie Andersen; Katie Anderson; Nancy E Mayo
Journal:  Pain Res Manag       Date:  2013 Sep-Oct       Impact factor: 3.037

8.  Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK.

Authors:  Ray Gani; Gavin Giovannoni; David Bates; Belinda Kemball; Steve Hughes; John Kerrigan
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

9.  Proteomics comparison of cerebrospinal fluid of relapsing remitting and primary progressive multiple sclerosis.

Authors:  Marcel P Stoop; Vaibhav Singh; Lennard J Dekker; Mark K Titulaer; Christoph Stingl; Peter C Burgers; Peter A E Sillevis Smitt; Rogier Q Hintzen; Theo M Luider
Journal:  PLoS One       Date:  2010-08-27       Impact factor: 3.240

10.  Pain acts through fatigue to affect participation in individuals with multiple sclerosis.

Authors:  Shahnaz Shahrbanian; Pierre Duquette; Sara Ahmed; Nancy E Mayo
Journal:  Qual Life Res       Date:  2015-08-09       Impact factor: 4.147
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.